Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer

Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Res
Asıl Yazarlar: Wali, Vikram B, Langdon, Casey G, Held, Matthew A, Platt, James T, Patwardhan, Gauri A, Safonov, Anton, Aktas, Bilge, Pusztai, Lajos, Stern, David F, Hatzis, Christos
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5582957/
https://ncbi.nlm.nih.gov/pubmed/27872098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1901
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller